- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
Pfizer Enters into Translational Research Collaboration with Adaptive Biotechnologies to Help Advance Novel Immuno-Oncology Solutions1/8/16 8:00 am ESTNEW YORK & SEATTLE--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise. Under the terms of the agreement, Pfizer and Adaptive will seek to combine drug development and platform technology biomarker expertise to identify patients who may preferentially benefit frommore...
Pfizer Invites Public to Listen to Webcast of Pfizer and Allergan Discussion at 34th Annual J.P. Morgan Healthcare Conference1/5/16 10:00 am ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a joint discussion with Pfizer and Allergan management at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 10:30 a.m. Pacific Standard Time. Pfizer speakers will be Ian Read, Chairman and CEO, Mikael Dolsten, President, Worldwide Research and Development, and Albert Bourla, Group President, Vaccines, Oncology and Consumermore...
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer1/4/16 8:00 am EST
DARMSTADT, Germany & NEW YORK & WALTHAM, Mass.--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s entinostat, an investigational oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells and regulatory T-cells), in patients with heavily pre-treated,more...
- Merck KGaA, Darmstadt, Germany, Pfizer and Syndax will collaborate to investigate safety, tolerability and preliminary efficacy of avelumab and entinostat in advanced ovarian cancer
12/22/15 10:00 am ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 2, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2015 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.more...
Merck KGaA, Darmstadt, Germany and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab12/22/15 8:00 am EST
DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany and Pfizer today announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer. The JAVELIN Ovarian 200 trial is the first Phase III study of a PD-L1 inhibitor investigated as a treatment for platinum-resistant/refractory ovarian cancer. The alliance alsomore...
- Initiation of Phase III JAVELIN Ovarian 200 trial investigating avelumab as a treatment for platinum-resistant/refractory ovarian cancer
- Initiation of Phase III JAVELIN Bladder 100 trial investigating avelumab as a maintenance treatment, in the first-line setting, for patients with urothelial cancer
- Merck KGaA, Darmstadt, Germany-Pfizer Alliance achieves 2015 goal of initiating six pivotal trials with JAVELIN Ovarian 200 and JAVELIN Bladder 100 trials
Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder12/21/15 4:00 pm ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced the top line results from a Phase 3 study which evaluated the efficacy, safety, and tolerability of Pristiq® (desvenlafaxine succinate sustained-release formulation) in pediatric patients ages 7 to 17 with Major Depressive Disorder (MDD). The study did not meet its primary objective to demonstrate superior efficacy of desvenlafaxine succinate sustained-release formulation compared to placebomore...
12/14/15 4:30 pm EST
Board of Directors Approves Increase in Quarterly Cash Dividend to $0.30 Per ShareNEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 30-cent first-quarter 2016 dividend on the company’s common stock, payable March 2, 2016, to shareholders of record at the close of business on February 5, 2016. Pfizer increased the dividend by approximately 7 percent, to 30 cents from 28 cents per share. The first-quarter 2016 cash dividend will be the 309th consecutive quarterly dividend paid by Pfizer. “Themore...
12/14/15 10:30 am ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Guggenheim 3rd Annual Boston Healthcare Conference on Tuesday, December 15, 2015 at 12:00 p.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Guggenheim 3rd Annual Boston Healthcare Conferencemore...
AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy12/10/15 4:15 pm EST
Results of the subanalyses at each time interval (7, 21, and 90 days) were consistent with the overall results of the Eliquis Phase 3 AMPLIFY trial at 6 months and were published in Thrombosis and HaemostasisNEW YORK PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results from a post-hoc early time course subanalysis of the Phase 3 AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-Line Therapy) trial. The subanalysis demonstrated Eliquis (apixaban) was comparable to conventional therapy (subcutaneous enoxaparin overlapped and followed by oral warfarin dose-adjustedmore...
Pfizer Announces FDA Acceptance of IBRANCE® (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer12/10/15 8:00 am EST
sNDA seeks new indication to expand approved use of IBRANCE based on data from Phase 3 PALOMA-3 trialNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review for a supplemental New Drug Application (sNDA) for Pfizer’s breast cancer medication, IBRANCE® (palbociclib). If approved, the sNDA would expand the approved use of IBRANCE to reflect findings from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE in combination with fulvestrant versus fulvestrant plusmore...